Document Type
Article
Publication Date
8-29-2024
Original Citation
Mehdi S,
Xu Y,
Shultz LD,
Kim E,
Lee Y,
Kendrick S,
Yoon D.
Development of New Diffuse Large B Cell Lymphoma Mouse Models. Cancers (Basel). 2024;16(17):3006.
Keywords
JMG
JAX Source
Cancers (Basel). 2024;16(17):3006.
ISSN
2072-6694
PMID
39272864
DOI
https://doi.org/10.3390/cancers16173006
Grant
This work was supported by the UAMS Winthrop P. Rockefeller Cancer Institute Seeds of Science Award (DY), the National Institutes of Health (P20GM121293; SK and CA034196; LS), and Department of Defense PRCRP (CA210778; SK).
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most diagnosed, aggressive non-Hodgkin lymphoma, with ~40% of patients experiencing refractory or relapsed disease. Given the low response rates to current therapy, alternative treatment strategies are necessary to improve patient outcomes. Here, we sought to develop an easily accessible new xenograft mouse model that better recapitulates the human disease for preclinical studies. We generated two Luciferase (Luc)-EGFP-expressing human DLBCL cell lines representing the different DLBCL cell-of-origin subtypes. After intravenous injection of these cells into humanized NSG mice, we monitored the tumor growth and evaluated the organ-specific engraftment/progression period. Our results showed that human IL6-expressing NSG (NSG-IL6) mice were highly permissive for DLBCL cell growth. In NSG-IL6 mice, systemic engraftments of both U2932 activated B cell-like- and VAL germinal B cell-like-DLBCL (engraftment rate; 75% and 82%, respectively) were detected within 2nd-week post-injection. In the organ-specific ex vivo evaluation, both U2932-Luc and VAL-Luc cells were initially engrafted and expanded in the spleen, liver, and lung and subsequently in the skeleton, ovary, and brain. Consistent with the dual BCL2/MYC translocation association with poor patient outcomes, VAL cells showed heightened proliferation in human IL6-conditioned media and caused rapid tumor expansion and early death in the engrafted mice. We concluded that the U2932 and VAL cell-derived human IL6-expressing mouse models reproduced the clinical features of an aggressive DLBCL with a highly consistent pattern of tumor development. Based on these findings, NSG mice expressing human IL6 have the potential to serve as a new tool to develop DLBCL xenograft models to overcome the limitations of standard subcutaneous DLBCL xenografts.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.